As the COVID-19 pandemic has shown, the medical product and pharmaceutical supply chain can be considered a matter of national security. The Silverwood Partners Healthcare team has considered in the attached analysis (Click here to download) how continuous manufacturing and investment in the lab tools that support it can help repatriate medical manufacturing in the U.S.
- The Trump Administration is preparing an Executive Order to bring pharmaceutical manufacturing back into the U.S., making a cost-effective domestic solution imperative.
- A drive has begun to bring back to the U.S. the manufacturing of strategically important medical products and supplies (e.g. recent Kodak Pharmaceuticals initiative).
- The supply chain for many products is global, whereas national security concerns now demand that the U.S. takes control over materials and manufacturing.
- Keeping the cost of products low has driven globalization, so cost-effective solutions must be a part of any proposal to bring manufacturing back to the U.S.
- Continuous Manufacturing has demonstrated cost effectiveness, but it requires new capabilities, especially in quality assurance and quality control.
- Bringing manufacturing back to the U.S. will provide an opportunity to invest in tools that have significant market opportunities not only in healthcare but also in other related sectors.